TGBA01AD
| Clinical data | |
|---|---|
| Other names | FKB01MD |
| Routes of administration | By mouth |
| Pharmacokinetic data | |
| Bioavailability | 17%[1] |
| Elimination half-life | 4 hours[1] |
| Chemical and physical data | |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2][1] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]
See also
References
- 1 2 3 "FKB01MD". Fabre-Kramer.
- ↑ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
- ↑ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.